Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

VPHOP · Osteoporotic Virtual Physiological Human

FP7Status: CLOSED1 September 200831 October 2012EU funding €9,184,863

Nearly four million osteoporotic bone fractures cost the European health system more than 30 billion Euro per year. This figure could double by 2050. After the first fracture, the chances of having another one increase by 86%. We need to prevent osteoporotic fractures. The first step is an accurate prediction of the patient-specific risk of fracture that considers not only the skeletal determinants but also the neuromuscular condition. The aim of VPHOP is to develop a multiscale modelling technology based on conventional diagnostic imaging methods that makes it possible, in a clinical setting, to predict for each patient the strength of his/her bones, how this strength is likely to change over time, and the probability that the he/she will overload his/her bones during daily life. With these three predictions, the evaluation of the absolute risk of bone fracture will be much more accurate than any prediction based on external and indirect determinants, as it is current clinical practice. These predictions will be used to: i) improve the diagnostic accuracy of the current clinical standards; ii) to provide the basis for an evidence-based prognosis with respect to the natural evolution of the disease, to pharmacological treatments, and/or to preventive interventional treatments aimed to selectively strengthen particularly weak regions of the skeleton. For patients at high risk of fracture, and for which the pharmacological treatment appears insufficient, the VPHOP system will also assist the interventional radiologist in planning the augmentation procedure. The various modelling technologies developed during the project will be validated not only in vitro, on animal models, or against retrospective clinical outcomes, but will also be assessed in term of clinical impact and safety on small cohorts of patients enrolled at four different clinical institutions, providing the factual basis for effective clinical and industrial exploitations.

Consortium · 22 organisations

coordinator

ISTITUTO ORTOPEDICO RIZZOLI

IT · €1,542,015

participant

EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH

DE · €726,670

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €161,100

participant

THE UNIVERSITY OF SHEFFIELD

UK · €253,125

participant

ARTS ASSOCIATION

FR · €202,119

participant

UNIVERSITE DE GENEVE

CH · €349,060

participant

SCS SRL

IT · €782,400

participant

UNIVERSITAET BERN

CH · €363,696

participant

BRAINLAB AG

DE · €85,400

participant

UPPSALA UNIVERSITET

SE · €239,199

participant

ANSYS FRANCE SAS

FR · €61,625

participant

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

CH · €1,027,376

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €1,041,308

participant

ZAPADOCESKA UNIVERZITA V PLZNI

CZ · €72,240

participant

UNIVERSITY OF BEDFORDSHIRE

UK · €343,419

participant

PHILIPS MEDICAL SYSTEMS NEDERLAND BV

NL · €35,000

participant

TECHNISCHE UNIVERSITEIT EINDHOVEN

NL · €812,657

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €212,319

participant

EOS IMAGING SA

FR · €272,529

participant

SYLVIA LAWRY CENTRE FOR MULTIPLE SCLEROSIS RESEARCH E.V.

DE · €128,232

participant

HASKOLI ISLANDS

IS · €203,199

participant

ANSYS FRANCE SAS

FR · €270,175

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.